$ARWR Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). AUTHOR(S) Othon Iliopoulos, Eric Jonasch, Frede Donskov, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Sarah J. Welsh, Sanjay Thamake, Rodolfo F. Perini, Eric K. Park, W. Marston Linehan, Ramaprasad Srinivasan, W. Kimryn Rathmell ABSTRACT 333 Looks like Merck will be releasing more data at ASCO... Obviously I was looking for my favorite company ARWR to be there, but this was all I found after paging through 97 abstracts... your welcome! At least we'll have data to compare to someday hopefully soon... unlike most of our drugs they really don't have any great comparisons/competition, but this will be the exception!
  • 6